Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to access the Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer Enduring Educational Symposium that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Sunday, June 14, 2026.
This educational activity is supported by an independent medical education grant from GSK.
Course Description
The era of antibody–drug conjugates (ADCs) in gynecologic oncology have shifted from promise to intense competition. In ovarian and endometrial cancers, platforms targeting FRα, HER2/HER3, TROP2, B7-H4, CDH6, and NaPi2b are advancing rapidly. Mirvetuximab soravtansine has improved outcomes for FRα-positive ovarian cancer, while trastuzumab deruxtecan has extended HER2-directed therapy to certain endometrial tumors. Next-generation ADCs are improving antigen selection, internalization, payload potency, and linker stability to address antigen heterogeneity, resistance, and class-specific toxicities highlighted in recent studies. This symposium will provide a clear, evidence-based overview of the ADC landscape. Faculty will differentiate competing designs, evaluate key and emerging trial data, and offer practical guidance on sequencing, toxicity management, and biomarker-driven patient selection. The program will also highlight active trials and company strategies shaping future standards of care, ensuring participants are prepared to incorporate ADC advances into practice with confidence and clarity.
